PARP Inhibitor in clinical trials Molecular bases of the treatment of Alzheimer

macol Exp Ther 2004a,308:609 PARP Inhibitor in clinical trials 616. Verdaguer E, Jorda EG, Stranges A, Canudas AM, Jimenez A, Sureda FX, Pallas M, Camins A. Inhibition of CDKs: a strategy for preventing kainic acid induced apoptosis in neurons. Ann N Y Acad Sci 2003a,1010:671 674. Verdaguer E, Jorda EG, Canudas AM, Jimenez A, Pubill D, Escubedo E, Camarasa J, Pallas M, Camins A. Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle related mechanism. Neurochem Int 2004b,44:251 261. Verdaguer E, Jorda EG, Canudas AM, Jimenez A, Sureda FX, Rimbau V, Pubill D, Escubedo E, Camarasa J, Pallas M, Camins A. 3 Amino thioacridone, a selective cyclin dependent kinase 4 inhibitor, attenuates kainic acid induced apoptosis in neurons. Neuroscience 2003b,120:599 603.
Vina J, Lloret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer,s disease with antioxidants: prevention of oxidative stress. sumatriptan Mol Aspects Med 2004,25:117 123. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer,s disease brain. J Neurosci 1997,17:3588 3598. Wang CX, Shuaib A. Neuroprotective effects of free radical scavengers in stroke. Drugs Aging 2007,24:537 546. Wang F, Corbett D, Osuga H, Osuga S, Ikeda JE, Slack RS, Hogan MJ, Hakim AM, Park DS. Inhibition of cyclin dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J Cereb Blood Flow Metab 2002,22:171 182. Wang H, Reiser G. The role of the Ca2 sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes.
J Neurochem 2003a,84:1349 1357. Wang H, Reiser G. Thrombin signaling in the brain: the role of protease activated receptors. Biol Chem 2003b,384:193 202. Wang LH, Besirli CG, Johnson EM Jr. Mixed lineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004,44:451 474. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 2004,18:790 804. Liu et al. Page 17 Neurobiol Dis. Author manuscript, available in PMC 2011 March 1. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P. The cyclindependent kinase inhibitor seliciclib decreases the expression of mitotic control genes and prevents entry into mitosis.
Cell Cycle 2007,6:3114 3131. Williams M. Progress in Alzheimer,s disease drug discovery: an update. Curr Opin Investig Drugs 2009,10:23 34. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid beta peptide exposure: involvement of Src family protein kinases. J Neurosci 2002,22:10 20. Wyatt PG, et al. Identification of N 4 1H pyrazole 3 carboxamide, a novel cyclin dependent kinase inhibitor using fragment based X ray crystallography and structure based drug design. J Med Chem 2008,51:4986 4999. Xi G, Reiser G, Keep RF.
The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003,84:3 9. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006,5:53 63. Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharideinduced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008,5:4. Xue M, Hollenberg MD, Yong VW. Combination of thrombin and matrix metalloproteinase 9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006,26:10